9704937-4

RTMP COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/35, 31/40 — A1

(11) International Publication Number: WO 96/33710

(43) International Publication Date: 31 October 1996 (31.10.96)

(21) International Application Number: PCT/SE96/00526

(22) International Filing Date: 23 April 1996 (23.04.96)

(30) Priority Data:
9501567-3 27 April 1995 (27.04.95) SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: EVENDEN, John [GB/SE]; Markvardsgatan 3, S-113 53 Stockholm (SE). THORBERG, Seth-Olov [SE/SE]; Gullvivsstigen 42, S-153 31 Järna (SE).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

With amended claims.

(54) Title: A COMBINATION OF A 5-HT UPTAKE INHIBITOR WITH A SELECTIVE 5-HT$_{1A}$ ANTAGONIST

(57) Abstract

The invention relates to a combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is selective 5-HT$_{1A}$ antagonist of general formula (I), wherein R_1 is n-propyl or cyclobutyl; R_2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl; R_3 is hydrogen; R_4 is hydrogen or methyl; as (R)-enantiomer in the form of free base or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combination, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as a kit containing said combination.



(I)